# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's comme...
HC Wainwright & Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target...
B of A Securities analyst Jason Zemansky maintains Cytokinetics (NASDAQ:CYTK) with a Neutral and lowers the price target fro...
Barclays analyst Carter Gould maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $100 t...
Cytokinetics shares are trading lower by 15.8% during Thursday's session. The company announced the pricing of a public off...